Search This Blog

Friday, July 17, 2026

IRGC says it hit Thai-flagged ship in Strait of Hormuz

 

Iran says the Revolutionary Guard's navy targeted a Thai-flagged ship in the Strait of Hormuz on Friday after the vessel "ignored warnings and attempted to transit without obtaining permission."

A video published by IRGC-affiliated media appeared to show damage to the vessel.

https://www.iranintl.com/en/liveblog/202607116587

Iran state TV disputes Al Jazeera report of Bushehr strike damage

 

Iran’s state-run Press TV has rejected an Al Jazeera report that satellite imagery showed damage inside the Bushehr nuclear power plant complex following US strikes.

Al Jazeera said Sentinel-2 images taken on July 7 and 12 revealed impact scars within the complex and another apparent strike site in nearby support facilities.

Press TV said an on-site investigation and inquiries with Iranian officials found no evidence that the plant itself had been hit. It said the strikes landed outside the facility’s boundaries and that the darkened area identified in the imagery was green space outside the plant’s operational and sensitive sections.

https://www.iranintl.com/en/liveblog/202607116587

'AP: Trump Admin Revives Rule That May Deny Green Cards to Immigrants Who Use Medicaid'

 The Trump administration is reviving a rule that could deny green cards to immigrants who use public benefits that could include food stamps, Medicaid, housing vouchers, and others.

The policy, known as "public charge," appeared on Thursday in the Federal Register. It will be formally published on July 20 and take effect Sept. 18. Under the policy, applicants for green cards have to show they wouldn't be burdens to the country or "public charges."

The policy was first implemented in February 2020 as one of President Donald Trump's moves to limit legal immigration during his first administration, but it was reversed after Democratic President Joe Biden came to power.

Its return comes when the Republican administration is implementing a hard-line policy to curb both illegal and legal immigration, and when the cost of healthcare and food is rising.

The federal government "is reaffirming the requirement of self-reliance, protecting public resources, and ending policies that encouraged dependency on the backs of hard-working American taxpayers," U.S. Citizenship and Immigration Services (USCIS) said in a post published on its X account.

"Under President Trump, USCIS is restoring the basic principle that immigrants must be able to support themselves," the post said.

While the administration's crackdown on immigration has an increased focus on deportations and immigration enforcement in cities across the country and at borders and entry points, it has also taken actions that target legal immigrants and mixed-status families, in which the parents are foreign nationals with U.S.-born children.

The Rule Expands Disqualification Options

Federal law already requires those seeking permanent residency or legal status to demonstrate that they will not become a public charge. The Trump administration's rule, however, broadens the grounds for disqualification.

The new rule does not describe or specify by name the benefits and programs that could be considered a public charge. Instead, it says that officers who would implement the policy will make "individualized, fact-specific public charge inadmissible determinations, based on a totality of the alien's circumstances."

It says that, "using good judgment and discretion, officers will more accurately assess an alien's likelihood at any time of becoming a public charge."

The Trump administration first promoted the rule in 2018 as a way to ensure that only those who were self-sufficient came to the U.S.

Immigrant rights advocates criticized it, saying it amounted to a "wealth test." Public health experts said it would lead to worse health outcomes.

Manatt Health, a group that provides advice to state and federal governments, estimated the policy would have deterred as many as 26 million people from seeking healthcare, food, housing, or other aid through programs for which they qualified under federal law. About half were U.S. citizens, mostly children or adults living in a mixed-status family, according to the group.

Experts also noted that most people who receive benefits from the government are already legal residents.

A 2020 study from the Migration Policy Institute said that while the "chilling effects" may be vast, the number of immigrants who could be deemed ineligible for legal permanent residence based on use of one of the public benefits under the rule was small.

The institute estimated that no more than 167,000 people -- less than 1% of the 22.1 million noncitizens residing in the United States at that time -- could be determined ineligible for a green card based on their current use of a listed benefit.

There were 22.8 million noncitizens living in the U.S. in 2023, according to the Census Bureau.

Organizations including the American Academy of Pediatrics (AAP) said the policy generates confusion and fear and will cause immigrants and their U.S.-born relatives to decide not to apply for benefits and services to which they're entitled.

"When children miss out on the care and services designed to support them, their overall health and well-being suffers needlessly," said AAP President Andrew Racine, MD, PhD. "Policies like this put children's health at risk and make our communities less healthy."

https://www.medpagetoday.com/publichealthpolicy/medicaid/122239

'AP: How Wildfire Smoke Attacks the Body'

 Smoke from wildfires -- which are burning more of the Northern Hemisphere as Earth warms -- attacks nearly every system in the human body, killing tens of thousands of people a year, numerous medical studies show.

It attacks the body immediately, spiking asthma cases with increased ambulance runs within hours, and swamps emergency departments in a day or so with people suffering from heart attacks and other cardiovascular and lung issues, as well as mental health issues, doctors and scientists told the Associated Press.

Smoke also harms pregnant women, increasing the risk of premature births and low-weight babies who could have breathing problems the rest of their lives, doctors and studies say. And then there are long-term risks connecting prolonged smoke and other air pollution exposure to some cancers and dementia.

After huge global fires in 2018 and 2019, the medical and science communities started looking at the health effects from the smoke with "more and more studies coming out finding that there's all types of impacts that may not have been so obvious before," said Mary Johnson, MD, PhD, a Harvard School of Public Health environmental health scientist.

Smoke causes inflammation by triggering the body's immune system to go into overtime to fight the irritant. Scientists have found it can harm the brain, the skin, and men's sperm, with almost no system of the body spared, Johnson said. People over 60 become more prone to stroke in wildfire smoke, she said.

"Wildfire smoke is the toxic product of combustion of whatever burned," which could include houses and cars, said Courtney Howard, MD, an emergency department physician, chair of the Global Climate and Health Alliance, and president-elect of the Canadian Medical Association.

"So really it's a big giant toxic soup of particles and gases," she added.

Scientists have counted at least 1,000 toxins in wildfire smoke, according to Colorado State University environmental toxicologist Luke Montrose, PhD.

"If I gave you a list, you would recognize some of these as being very bad, oftentimes associated with the burning of diesel fuel or cigarette smoke, things like formaldehyde or volatile organic compounds," Montrose said. "So just the smoke itself can be bad."

Rising Global Temperatures From Climate Change Means More Fires

So far this year, more than 5,740 square miles of the U.S. has burned from wildfires, which is 31% more than the average of the previous 10 years on this date, according to the National Interagency Fire Center. The amount of U.S. land burned each year in the 2020s -- averaged out over a decade -- is now more than twice what it was 30 years ago.

Europe saw a record high amount of land burned in 2025, Canada has had several record or near-record fire years in the 2020s, and the Arctic recently has had unprecedented levels of burning.

"Wildfires are becoming more frequent and intense because of climate change, and when a fire happens, you have smoke," said Colleen Reid, PhD, MPH, a University of Colorado geographic health professor.

Most of the biggest particles in wildfire smoke fall close to where a blaze is burning, while the smallest particles -- the ones that scientists say do the most damage -- travel the farthest. In a typical wildfire, the nasty particles that harm human health are about the size of one micron, Reid said.

Inside the Body, Particles Attack

First those particles have to get by your body's protection, mainly nose hairs and mucus, then they get into your lungs and from there the bloodstream.

Montrose said the particles can be coated in lots of chemicals and have large surface areas. That triggers the body's defense system to "send signals to other cells that say, 'We have a problem. We need to mount an immune response to this.' And that's where you get your acute effect or your effect within minutes, hours, or even that day." It's mostly happening in the hearts and lungs, he said.

And many people die.

On average 24,100 people died each year in the Lower 48 states between 2006 and 2020 due to long-term exposure to tiny particles from wildfire smoke, according to a study this year in the journal Science Advances. A Stanford study projects that U.S. wildfire smoke deaths will increase with climate change and by midcentury hit an annual cost of $244 billion in terms of the economic value the government puts on each life.

On a global scale, wildfire smoke particles cause 677,745 deaths annually, with almost 39% of them children under age 5, according to a 2021 study that combined observations, studies on how the body responds to the particles, and computer models to calculate the toll.

The biggest nonlethal effects have to do with the way people breathe, especially those with asthma.

"We did a study here in 2014 after we had about two-and-a-half months of smoke off and on, because we're in the subarctic so we're warming at triple the global rate, so in a way we're kind of canaries in the coal mine of the health impacts of climate change," Howard said on a clear day from Yellowknife, Canada. "We found a full doubling of emergency department visits for asthma and about a 50% increase in pneumonia."

"Even in individuals that don't have asthma, the air can be so irritating that you could have difficulty with your respiratory system regardless," Johnson said, "whether it's coughing, whether it's chest tightness, whether it's sore throat, headache."

There Are Ways to Minimize the Risks

Studies have linked smoke to people having more trouble with decision making and other cognitive issues. People come to the emergency department depressed, Howard said. That's why it's important to find a place with clean air -- including designated shelters or libraries -- to get a break from the smoke and possibly exercise, she said.

Experts suggest people wear high-quality masks when outdoors, even though they don't provide perfect protection. Inside, check windows and doors for seals, invest in a good ventilation system, and check air filters, they say.

"Staying away from the smoke is No. 1 if you can," Johnson said.

https://www.medpagetoday.com/publichealthpolicy/environmentalhealth/122238

New Agents for AMD Preserve Vision, Dramatically Reduce Treatment Burden

 An investigational bispecific antibody for retinal disease achieved faster and numerically greater short-term improvements in visual acuity and retinal anatomy versus faricimab (Vabysmo), a randomized, proof-of-concept trial showed.

Patients randomized to either of two doses of OLN324 had a two-letter improvement in visual acuity versus faricimab at 20 weeks, more rapid improvement in retinal fluid, and faster and numerically greater reductions in pigment epithelial detachment thickness (PED). Durability was comparable as 82% of patients treated with the higher dose of OLN324 went 12 weeks without retreatment, as did 81% of patients assigned to faricimab.

No patient assigned to the investigational angiopoietin 2 (Ang2)/VEGF inhibitor developed intraocular inflammation, retinal vasculitis, occlusive retinal vasculitis, or endophthalmitis, reported David Eichenbaum, MD, of Retina Vitreous Associates of Florida in St. Petersburg, at the American Society of Retina Specialists meeting.

During a discussion, moderator Charles Wykoff, MD, PhD, of Retina Consultants of Texas in Houston, who was a co-author on the study, asked about progress toward finding biomarkers to identify patients who need Ang2 inhibition in addition to VEGF inhibition.

"Prospectively, it's tough," said Eichenbaum. "I think the best Ang2 biomarker we have to show differentiation with that blockade is still fluorescein angiography and diabetes [to look for retinal leakage]. That is a narrative we can build on with other novel biologies, too. Is there something to reduce leakage? Is there something in the blood-retinal barrier? Is there something that Ang2 or other biologies are doing that's beneficial that we just don't see with OCT [optical coherence tomography]? We've got to figure that out."

Two gene therapies for retinal disease also showed promise for slowing progression of neovascular age-related macular degeneration (nAMD) and preserving vision. Continued follow-up in a phase II trial of ixoberogene soroparvovec (ixo-vec) intravitreal gene therapy showed durable vision preservation and maintenance of retinal anatomy at 2 years. Additionally, two-thirds to three-fourths of patients treated with two different doses of the therapy averaged one or fewer injections per year, said Shawn Kavoussi, MD, of the Texas Retina Center in Houston.

Initial clinical data for the adeno-associated virus (AAV) gene therapy NG101 showed preservation of vision and retinal anatomy for up to a year and a 90% reduction in annualized injections of anti-VEGF therapy. No dose-limiting toxicities or NG101-related serious adverse effects (SAEs) have occurred, said Peter J. Kertes, MD, of the University of Toronto.

OLN324

Like faricimab, OLN324 inhibits both Ang2 and VEGF but has 60 times greater potency for Ang2 inhibition, said Eichenbaum. A smaller molecular size facilitates better tissue penetration, and the bispecific has a higher molar dose than faricimab 6 mg and aflibercept (Eylea) 2 mg and 8 mg.

The bispecific antibody was evaluated in the randomized phase I JADE trial comparing two doses of OLN324 and faricimab. The trial included 80 patients with previously untreated nAMD and 84 with diabetic macular edema (DME). Eichenbaum reported findings only for the nAMD group.

The primary objective was safety and tolerability at week 12 with continued follow-up to week 20. Visual acuity and various measures of retinal anatomy were exploratory efficacy objectives.

The primary objective was met. Improvement in visual acuity was evident within a week after the initial injection of OLN324, and both doses of the bispecific led to numerically greater improvement through week 20 (+8.6 and +8.4 letters vs +6.4 letters with faricimab). All three treatment groups had rapid and sustained improvement in retinal fluid, and at 20 weeks the mean change from baseline in central subfield thickness (CST) was -128 and -142 µm with OLN324 and -142 µm with faricimab. PED thickness declined within the first week in all three groups and remained numerically greater in the OLN324 groups.

A phase III trial of OLN324 in DME and nAMD is expected to begin later this year, according to a statement from Ollin Biosciences.

Ixo-Vec

The gene therapy promotes continuous production of aflibercept with the goal of preserving vision and retinal anatomy while reducing treatment burden. Kavoussi reported 2-year follow-up data from the phase II LUNA trial involving 60 patients with stable nAMD treated with an average of 10 anti-VEGF intravitreal injections in the previous year. An earlier report showed no significant deterioration of visual acuity or retinal anatomy at 52 weeks, and 54-69% of patients remained injection free for 12 months.

The update continued to show stable visual acuity and minimal change in CST. Annualized injection frequency declined from 10 at baseline to 0.9 to 1.1 at 2 years, approximately a 90% reduction.

No SAEs, episcleritis, vasculitis, retinitis, choroiditis, occlusive events, or hypotony occurred with either dose of ixo-vec. All patients received corticosteroid prophylaxis (randomized 2:1 to local or oral), and criteria for aflibercept rescue were an increase in CST >75 µm from baseline, loss of ≥10 letters of vision, or new vision-threatening hemorrhage.

Two phase III trials of the gene therapy are ongoing.

NG101

Administered by subretinal injection, the gene therapy uses an AAV vector to deliver a construct that includes a proprietary CAT311 promoter to achieve sustained high-level aflibercept expression, said Kertes. The construct allows for dosing that is orders of magnitude lower than other gene therapies.

The phase I SENSE trial in nAMD consisted of three cohorts and a cumulative total of 20 patients treated with one of three doses of NG101. The patients had a mean age of 76, best corrected visual acuity of 57.3 letters (minimum of 20), and at least three anti-VEGF injections in the previous 6 months. The primary endpoint was incidence and severity of adverse events at 24 weeks

The trial met the safety/tolerability endpoint. Preliminary efficacy data for the first two cohorts (n=12, follow-up 44 to 52 weeks) showed that the patients had annualized anti-VEGF injection rates of 8-10, which was reduced by about 90% in both groups to 0-1. Best corrected visual acuity improved by 0.2-2.4 letters, and mean CST increased by 57 µm in one group and 31 µm in the other.

A phase IIb trial is expected to begin during the first quarter of 2027, said Kertes.

Disclosures

Wykoff and Eichenbaum each submitted an extensive list of financial disclosures.

Kavoussi disclosed relationships with 4DMT, AbbVie, Adverum, Alcon, BioAge, EyePoint, Kodiak Science, Ocular Therapeutix, Oculgen, Samsara, Alimera, Allergan, Heidelberg Engineering, Intelligent Retinal Imaging Systems, Iridex, Regeneron, and Volk.

Kertes disclosed relationships with Amgen, Novartis, Bayer, Roche, RegenxBio, Apellis, Astellas, Zeiss, Johnson & Johnson, Kriya Therapeutics, Elisigen, and Apotex.

Best Way to Test for Cyclospora Infection

 Routine ova and parasite (O&P) testing is likely to miss a Cyclospora infection, so physicians should be sure to request additional methods when searching for a diagnosis, testing experts said.

"The thing physicians may not know is if you order a test for O&P, you're not going to get it," Thomas A. Moore, MD, an infectious diseases physician at the University of Kansas School of Medicine–Wichita, told MedPage Today. "You have to specifically ask for Cyclospora" via staining that isn't routinely done, he said.

The modified acid-fast stain can sufficiently detect the parasite by dyeing it an easily identifiable color in a stool sample under the microscope, experts said.

There's also ultraviolet fluorescence microscopy, which makes the parasite "glow" in a way that chemical staining might miss. This, however, is not used as commonly, they noted.

Looking for the parasite's DNA is another option, usually via multiplex gastrointestinal polymerase chain reaction (GI-PCR). Moore likes the multiplex panel because it's a "catchall."

"So, if it happens to be Cyclospora, great, but if it's not, you know what else it is," as patients can be infected with other organisms, he noted.

Still, Moore emphasized that "you have to tell the lab, wherever you send it, that you suspect Cyclospora" because not all multiplex panels include this parasite.

Joel Barratt, PhD, a molecular parasitologist at Emory University School of Medicine in Atlanta, pointed out that DNA tests are "far more expensive" than microscopy, but also more sensitive. (Physicians on social media have reported out-of-pocket costs of up to $1,000 for DNA testing.)

When there are very few parasites in a sample, they may not be immediately obvious under a microscope -- but their DNA can still be detected, Barratt said.

"If cost is not a consideration, then PCR-based tests are more likely to detect a true Cyclospora infection than microscopy," he said. But "if you are worried about cost, microscopy-based tests are cheaper and will detect a Cyclospora infection most of the time, if one is present."

Also, if microscopy returns a negative test, and Cyclospora is still strongly suspected -- for example, if the patient ate produce known to carry the parasite, such as iceberg lettuce -- a multiplex GI-PCR panel can confirm whether the negative microscopy result is a true negative, Barratt added.

False positives are not common, Christopher Attaway, MD, a pathologist at the University of Vermont's Larner College of Medicine in Burlington, told MedPage Today. There is greater concern that cases might be missed because the parasite may not shed consistently. Testing multiple stool samples can increase the likelihood of detection, he added.

He noted that "in the real world, only the modified acid-fast stain of stool specimens and the multiplex GI-PCR panel are readily available," while UV fluorescence is "uncommon." He personally does not know any labs that offer it.

Attaway would recommend the multiplex GI-PCR panel for immunocompromised patients, but for otherwise healthy patients, the modified acid-stain is "perfectly fine."

And if clinical suspicion is high, both Moore and Attaway said it's reasonable to start treatment before tests confirm a case.

https://www.medpagetoday.com/infectiousdisease/publichealth/122242

Novartis First Complement Inhibitor Wins Full Approval in IgA Nephropathy

 The FDA fully approved iptacopan (Fabhalta) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression, drugmaker Novartis announced on Friday.

The complement inhibitor's conversion from accelerated to traditional approval hinged on findings from APPLAUSE-IgAN. The phase III study demonstrated a 48% reduction in the rate of estimated glomerular filtration rate (eGFR) decline compared with placebo over 24 months. Patients treated with iptacopan had an annualized mean change from baseline in eGFR of -3 mL/min/1.73 m² per year versus -5.7 mL/min/1.73 m² per year for those on placebo.

"The ability to significantly slow kidney function decline is a critical treatment goal," said investigator Dana Rizk, MD, of the University of Alabama at Birmingham, in the company's press release. "This approval of Fabhalta reinforces the importance of targeting underlying disease mechanisms, including complement activation, in treating IgAN to help preserve kidney health."

The treatment effect in the trial was consistent across all prespecified subgroups, indicating that iptacopan can mitigate kidney function decline in a broad population of patients with IgAN.

Iptacopan is a first-in-class Factor B inhibitor designed to selectively target the alternative complement pathway -- one of several key drivers of glomerular inflammation and kidney damage in IgAN. The drug also holds indications for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy.

As one of the most common autoimmune kidney diseases, IgAN is diagnosed in an estimated 2.5 per 100,000 adults worldwide each year. Approximately half of these patients progress to kidney failure or death within 10 to 20 years of diagnosis, which typically occurs in young adulthood.

Patients with the disease develop kidney damage due to an abnormal accumulation of IgA antibodies. This buildup damages the glomeruli, leading to inflammation, proteinuria, and potentially end-stage renal disease.

Iptacopan is the third IgAN therapy to receive traditional FDA approval, joining the corticosteroid budesonide (Tarpeyo) and the endothelin and angiotensin II receptor antagonist sparsentan (Filspari), following their own accelerated approvals.

A handful of other IgAN agents -- the endothelin receptor antagonist atrasentan (Vanrafia), the activity of a proliferation-inducing ligand (APRIL) blocker sibeprenlimab (Voyxact), and the dual APRIL/B-cell activating factor (BAFF) blocker atacicept (Trutakna) -- have also secured accelerated approvals based on proteinuria reduction, but the regulatory pathway requires confirmation of clinical benefit.

The safety profile of iptacopan remained consistent with previously reported data, with abdominal pain, dizziness, and nausea reported as the most common adverse events.

The drug carries a boxed warning for an increased risk of infections caused by encapsulated bacteria, and is only available through a risk evaluation and mitigation strategy program requiring appropriate vaccinations prior to treatment.

https://www.medpagetoday.com/nephrology/generalnephrology/122246